Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position Boosted by Quadrature Capital Ltd

Quadrature Capital Ltd increased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 373.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,002 shares of the company’s stock after purchasing an additional 72,555 shares during the quarter. Quadrature Capital Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,297,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter worth approximately $30,000. Blue Trust Inc. lifted its position in shares of Teva Pharmaceutical Industries by 92.3% during the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after acquiring an additional 2,180 shares during the last quarter. Psagot Value Holdings Ltd. Israel bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $57,000. Newbridge Financial Services Group Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $82,000. Finally, Desjardins Global Asset Management Inc. raised its position in shares of Teva Pharmaceutical Industries by 15.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after purchasing an additional 1,070 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the sale, the director now owns 981,000 shares in the company, valued at $16,706,430. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Amir Weiss sold 15,500 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the transaction, the chief accounting officer now owns 17,814 shares of the company’s stock, valued at $299,275.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 549,719 shares of company stock worth $9,353,736. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Stock Up 1.8 %

Shares of NYSE:TEVA traded up $0.30 during trading on Friday, reaching $17.10. 9,088,470 shares of the company traded hands, compared to its average volume of 8,597,557. The firm has a fifty day simple moving average of $16.76 and a 200 day simple moving average of $14.54. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. Teva Pharmaceutical Industries Limited has a 1-year low of $8.06 and a 1-year high of $17.69. The firm has a market cap of $19.37 billion, a P/E ratio of -41.71, a price-to-earnings-growth ratio of 1.48 and a beta of 0.90.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. The company had revenue of $3.82 billion during the quarter, compared to analyst estimates of $3.70 billion. Analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Barclays increased their price target on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, June 5th. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Finally, Piper Sandler reissued an “overweight” rating and set a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.56.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.